文献速递妇科

接受根治性放疗的宫颈癌患者的突变谱分析

Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy.
PubMed 文献 · Gynecol Oncol · 2020-09-18

该研究对98例接受根治性放疗的宫颈癌患者治疗前肿瘤活检标本进行409个癌症相关基因的外显子测序,发现FGFR家族基因突变率为24.5%,FGFR突变阳性患者5年无进展生存率显著低于突变阴性患者(43.9% vs 68.5%,P=0.010),多因素分析显示FGFR突变为5年PFS较差的显著预测因素(P=0.005)。

要点

  • FGFR家族基因突变率为24.5%,与PIK3CA和ARID1A突变率相近。
  • FGFR突变阳性患者5年PFS为43.9%,显著低于FGFR突变阴性患者的68.5%(P=0.010)。
  • 多因素分析显示FGFR突变是5年PFS较差的显著预测因素(P=0.005)。

核心结论

  • FGFR突变与接受根治性放疗的宫颈癌患者较差的PFS相关,这些结果需在前瞻性研究中进一步验证。

研究设计与样本

  • 研究纳入98例新诊断且病理确诊的宫颈癌患者(82例鳞状细胞癌、12例腺癌、4例腺鳞癌),均接受根治性放疗,从治疗前肿瘤活检标本提取DNA,使用下一代测序仪对409个癌症相关基因的外显子进行测序,识别基因突变并分析其与临床结局的相关性。

主要发现

  • 复发性突变见于PIK3CA(35.7%)、ARID1A(25.5%)、NOTCH1(19.4%)、FGFR3(16.3%)、FBXW7(19.4%)、TP53(13.3%)、EP300(12.2%)和FGFR4(10.2%)。
  • FGFR家族基因(即FGFR1-4)突变率为24.5%,与PIK3CA和ARID1A突变率相近。
  • 已识别的38个FGFR突变中,55%(21/38)位于FGFR蛋白酪氨酸激酶结构域。
  • FGFR突变阳性患者(n=24)5年无进展生存率为43.9%,显著低于FGFR突变阴性患者(n=74)的68.5%(P=0.010)。
  • 多因素分析显示FGFR突变是5年PFS较差的显著预测因素(P=0.005),独立于临床病理变量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些结果需在前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elucidate tumor mutation profiles associated with outcomes of uterine cervical cancer (UCC) patients treated with definitive radiotherapy. METHODS: Ninety-eight patients with newly diagnosed and pathologically confirmed UCC (82 squamous cell carcinomas, 12 adenocarcinomas, and four adenosquamous carcinomas) who were treated with definitive radiotherapy were analyzed. DNA was extracted from pre-treatment tumor biopsy specimens. The exons of 409 cancer-related genes were sequenced using a next-generation sequencer. Genetic mutations were identified and analyzed for correlations with clinical outcome. RESULTS: Recurrent mutations were observed in PIK3CA (35.7%), ARID1A (25.5%), NOTCH1 (19.4%), FGFR3 (16.3%), FBXW7 (19.4%), TP53 (13.3%), EP300 (12.2%), and FGFR4 (10.2%). The prevalence of mutations in FGFR family genes (i.e., FGFR1-4) was almost as high (24.5%) as that in PIK3CA and ARID1A, both of which are well-studied drivers of UCC. Fifty-five percent (21 of 38) of the identified FGFR mutations were located in the FGFR protein tyrosine kinase domain. Five-year progression-free survival (PFS) rates for FGFR mutation-positive patients (n = 24) were significantly worse than those for FGFR mutation-negative patients (n = 74) (43.9% vs. 68.5%, respectively; P = 0.010). Multivariate analysis identified FGFR mutations as significant predictors of worse 5 year PFS (P = 0.005), independent of clinicopathological variables. CONCLUSIONS: FGFR mutations are associated with worse PFS in UCC patients treated with definitive radiotherapy. These results warrant further validation in prospective studies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yoshimoto Y, Sasaki Y, Murata K, et al. Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy. Gynecol Oncol. 2020. PMID: 32951893. doi:10.1016/j.ygyno.2020.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。